SE0402976D0 - A medical product - Google Patents

A medical product

Info

Publication number
SE0402976D0
SE0402976D0 SE0402976A SE0402976A SE0402976D0 SE 0402976 D0 SE0402976 D0 SE 0402976D0 SE 0402976 A SE0402976 A SE 0402976A SE 0402976 A SE0402976 A SE 0402976A SE 0402976 D0 SE0402976 D0 SE 0402976D0
Authority
SE
Sweden
Prior art keywords
medical product
container
dose
optionally
inhalation
Prior art date
Application number
SE0402976A
Other languages
English (en)
Other versions
SE0402976L (sv
Inventor
Thomas Nilsson
Sven Calander
Alf Niemi
Claes Friberg
Lars Kax
Mattias Myrman
Original Assignee
Microdrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdrug Ag filed Critical Microdrug Ag
Priority to SE0402976A priority Critical patent/SE0402976L/sv
Publication of SE0402976D0 publication Critical patent/SE0402976D0/sv
Priority to US11/049,696 priority patent/US20060120969A1/en
Priority to BRPI0518600-5A priority patent/BRPI0518600A2/pt
Priority to CA002589118A priority patent/CA2589118A1/en
Priority to EP05801482A priority patent/EP1827381A1/en
Priority to AU2005310367A priority patent/AU2005310367A1/en
Priority to MX2007006533A priority patent/MX2007006533A/es
Priority to PCT/SE2005/001648 priority patent/WO2006059939A1/en
Priority to ZA200705376A priority patent/ZA200705376B/xx
Priority to JP2007544302A priority patent/JP2008521893A/ja
Priority to RU2007124795/15A priority patent/RU2007124795A/ru
Priority to KR1020077015300A priority patent/KR20070095927A/ko
Priority to CNA2005800476483A priority patent/CN101111226A/zh
Priority to US11/272,859 priority patent/US20060239933A1/en
Publication of SE0402976L publication Critical patent/SE0402976L/sv
Priority to IL183623A priority patent/IL183623A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Packages (AREA)
SE0402976A 2004-12-03 2004-12-03 Medicinsk produkt SE0402976L (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE0402976A SE0402976L (sv) 2004-12-03 2004-12-03 Medicinsk produkt
US11/049,696 US20060120969A1 (en) 2004-12-03 2005-02-04 Medical product for inhalation containing glucagon-like peptide-1 (GLP-1)
CNA2005800476483A CN101111226A (zh) 2004-12-03 2005-11-02 包含预期用于肺吸入的胰高血糖素样肽药物的医学产品
MX2007006533A MX2007006533A (es) 2004-12-03 2005-11-02 Un producto medico que comprende un medicamento peptidico tipo glucagon pretendido para inhalacion pulmonar.
JP2007544302A JP2008521893A (ja) 2004-12-03 2005-11-02 肺吸入用のグルカゴン様ペプチド薬物を含む医療品
EP05801482A EP1827381A1 (en) 2004-12-03 2005-11-02 A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
AU2005310367A AU2005310367A1 (en) 2004-12-03 2005-11-02 A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
BRPI0518600-5A BRPI0518600A2 (pt) 2004-12-03 2005-11-02 produto mÉdico compreendendo um medicamento de peptÍdeo tipo glucagon, idealizado para inalaÇço pulmonar
PCT/SE2005/001648 WO2006059939A1 (en) 2004-12-03 2005-11-02 A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
ZA200705376A ZA200705376B (en) 2004-12-03 2005-11-02 A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
CA002589118A CA2589118A1 (en) 2004-12-03 2005-11-02 A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
RU2007124795/15A RU2007124795A (ru) 2004-12-03 2005-11-02 Медицинский продукт, содержащий лекарственное средство на основе глюкагоноподобного пептида, предназначенное для легочной ингаляции
KR1020077015300A KR20070095927A (ko) 2004-12-03 2005-11-02 폐 흡입을 위한 글루카곤-형 펩타이드 약제를 포함하는의약품
US11/272,859 US20060239933A1 (en) 2004-12-03 2005-11-15 Medical product
IL183623A IL183623A0 (en) 2004-12-03 2007-06-03 A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402976A SE0402976L (sv) 2004-12-03 2004-12-03 Medicinsk produkt

Publications (2)

Publication Number Publication Date
SE0402976D0 true SE0402976D0 (sv) 2004-12-03
SE0402976L SE0402976L (sv) 2006-06-04

Family

ID=33550603

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402976A SE0402976L (sv) 2004-12-03 2004-12-03 Medicinsk produkt

Country Status (9)

Country Link
US (2) US20060120969A1 (sv)
JP (1) JP2008521893A (sv)
CN (1) CN101111226A (sv)
BR (1) BRPI0518600A2 (sv)
IL (1) IL183623A0 (sv)
MX (1) MX2007006533A (sv)
RU (1) RU2007124795A (sv)
SE (1) SE0402976L (sv)
ZA (1) ZA200705376B (sv)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ATE545652T1 (de) 1999-06-29 2012-03-15 Mannkind Corp Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
SE0402976L (sv) * 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
KR101736535B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
RU2467741C2 (ru) * 2007-10-24 2012-11-27 Маннкайнд Корпорейшн Доставка активных веществ
US8424518B2 (en) 2008-06-13 2013-04-23 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2853268A1 (en) 2009-01-08 2015-04-01 Mannkind Corporation Treatment of hyperglycemia with GLP-1
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
KR20180036807A (ko) * 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
JP5801997B2 (ja) * 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2011017554A2 (en) 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
RU2012138909A (ru) * 2010-03-31 2014-05-10 Гленмарк Фармасьютикалс Лимитед Фармацевтическая порошковая композиция для ингаляций
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US20150038674A1 (en) * 2013-08-05 2015-02-05 Bayrak Bertan Boran Use of glp-2 analogues in pulmonary diseases for therapeutic purpose
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MY193808A (en) 2016-01-11 2022-10-27 Syqe Medical Ltd Personal vaporizing device
WO2023224577A1 (en) * 2022-05-18 2023-11-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising micronized human insulin
CN115192554A (zh) * 2022-08-08 2022-10-18 浙江仙琚萃泽医药科技有限公司 无抛射剂的含肽吸入溶液剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
FI108518B (sv) * 1999-04-23 2002-02-15 Orion Yhtymae Oyj Pulverinhalator för kombinationsmedicin
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20010012829A1 (en) * 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
US7186683B2 (en) * 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
SE518397C2 (sv) * 2001-04-05 2002-10-01 Microdrug Ag Förfarande och anordning för frigörande av pulver och inhalatoranordning för administrering av medicinskt pulver
SE524990C2 (sv) * 2002-04-12 2004-11-09 Microdrug Ag Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver
SE0402976L (sv) * 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt

Also Published As

Publication number Publication date
CN101111226A (zh) 2008-01-23
US20060120969A1 (en) 2006-06-08
SE0402976L (sv) 2006-06-04
RU2007124795A (ru) 2009-01-10
JP2008521893A (ja) 2008-06-26
BRPI0518600A2 (pt) 2008-11-25
ZA200705376B (en) 2008-12-31
IL183623A0 (en) 2007-09-20
MX2007006533A (es) 2007-08-02
US20060239933A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
SE0402976D0 (sv) A medical product
BRPI0417155A (pt) produto medicinal compreendendo tiotrópio em um recipiente à prova de umidade
MY187036A (en) Inhalation device and method
MX2010008234A (es) Nueva dosificacion y formulacion.
WO2012041938A3 (en) Inhaler
CY1110636T1 (el) Προ-δοσιμετρημενος εισπνευστηρας ξηρης σκονης για φαρμακα ευαισθητα στην υγρασια
CY1110625T1 (el) Μεθοδος για την χορηγηση τιοτροπιου
MX2010008235A (es) Nueva dosificacion y formulacion.
DE602005016410D1 (de) Verbessertes medizinprodukt
SE0402345L (sv) Uppmätt läkemedelsdos
JP2004533438A5 (sv)
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina

Legal Events

Date Code Title Description
NAV Patent application has lapsed
NAV Patent application has lapsed